TY  - JOUR
AU  - Bennett, Gary G
AU  - Steinberg, Dori
AU  - Bolton, Jamiyla
AU  - Gallis, John A
AU  - Treadway, Cayla
AU  - Askew, Sandy
AU  - Kay, Melissa C
AU  - Pollak, Kathryn I
AU  - Turner, Elizabeth L
PY  - 2021
DA  - 2021/1/18
TI  - Optimizing an Obesity Treatment Using the Multiphase Optimization Strategy Framework: Protocol for a Randomized Factorial Trial
JO  - JMIR Res Protoc
SP  - e19506
VL  - 10
IS  - 1
KW  - text message
KW  - digital health
KW  - weight loss
KW  - personalized
AB  - Background: Effective weight loss interventions exist, yet few can be scaled up for wide dissemination. Further, none has been fully delivered via text message. We used the multiphase optimization strategy (MOST) to develop multicomponent interventions that consist only of active components, those that have been experimentally determined to impact the chosen outcome. Objective: The goal of this study is to optimize a standalone text messaging obesity intervention, Charge, using the MOST framework to experimentally determine which text messaging components produce a meaningful contribution to weight change at 6 months. Methods: We designed a 6-month, weight loss texting intervention based on our interactive obesity treatment approach (iOTA). Participants are randomized to one of 32 experimental conditions to test which standalone text messaging intervention components produce a meaningful contribution to weight change at 6 months. Results: The project was funded in February 2017; enrollment began in January 2018 and data collection was completed in June 2019. Data analysis is in progress and first results are expected to be submitted for publication in 2021. Conclusions: Full factorial trials are particularly efficient in terms of cost and logistics when leveraged for standalone digital treatments. Accordingly, MOST has the potential to promote the rapid advancement of digital health treatments. Subject to positive findings, the intervention will be low cost, immediately scalable, and ready for dissemination. This will be of great potential use to the millions of Americans with obesity and the providers who treat them. Trial Registration: ClinicalTrials.gov NCT03254940; https://clinicaltrials.gov/ct2/show/NCT03254940 International Registered Report Identifier (IRRID): RR1-10.2196/19506 
SN  - 1929-0748
UR  - http://www.researchprotocols.org/2021/1/e19506/
UR  - https://doi.org/10.2196/19506
UR  - http://www.ncbi.nlm.nih.gov/pubmed/33459600
DO  - 10.2196/19506
ID  - info:doi/10.2196/19506
ER  -